Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

33
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
33
Angina IV: Management01:26

Angina IV: Management

24
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
24

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endovascular repair of aortic coarctation and associated aneurysms with a thoracic branched endoprosthesis.

JTCVS structural and endovascular·2026
Same author

Rethinking endoleaks: is it time to change the name?

Journal of vascular surgery·2026
Same author

Exploring the role of ergothioneine and mycorrhizal fungi in shaping the wheat soil microbiome.

Environmental microbiome·2026
Same author

Transposition of the right renal artery to gastroduodenal artery for management of acute, symptomatic renovascular hypertension.

Journal of vascular surgery cases and innovative techniques·2026
Same author

Thirty-day outcomes following transcarotid artery revascularization with integrated embolic protection: The PERFORMANCE III study.

Journal of vascular surgery·2026
Same author

Globus pallidus externus (GPe) alpha band activity decreases after deep brain stimulation in clinically responsive obsessive-compulsive disorder patients.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: Sep 14, 2025

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.7K

Reintervention Rates for Restenting Versus Angioplasty Alone in Mesenteric Artery In-Stent Restenosis.

John P Taaffe1, Alice Alexander1, Andrew H Smith1

  • 1Department of Vascular Surgery, Cleveland Clinic, Cleveland, OH.

Annals of Vascular Surgery
|July 24, 2025
PubMed
Summary
This summary is machine-generated.

Restenting mesenteric artery in-stent restenosis (MAISR) reduces reinterventions compared to angioplasty alone. This study found restenting to be a more effective treatment for MAISR, leading to better patient outcomes and fewer repeat procedures within the first year.

More Related Videos

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

52
Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model
09:46

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model

Published on: September 14, 2009

13.9K

Related Experiment Videos

Last Updated: Sep 14, 2025

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.7K
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

52
Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model
09:46

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model

Published on: September 14, 2009

13.9K

Area of Science:

  • Vascular Surgery
  • Interventional Radiology
  • Gastroenterology

Background:

  • Mesenteric artery in-stent restenosis (MAISR) is a frequent complication after endovascular treatment for mesenteric ischemia.
  • MAISR significantly contributes to treatment failure in patients with mesenteric ischemia.

Purpose of the Study:

  • To analyze the range of endovascular interventions for MAISR at a major academic institution.
  • To compare 1-year clinical outcomes between angioplasty and stenting for MAISR.
  • To identify predictors of early reintervention in MAISR patients.

Main Methods:

  • A retrospective review of consecutive patients who underwent endovascular intervention for MAISR between 2008 and 2021.
  • Analysis of electronic medical records and imaging data.
  • Utilized univariable and Cox proportional hazard models to determine predictors of early reintervention.

Main Results:

  • 48 patients (54 vessels) were treated for MAISR; 38.8% received angioplasty alone, and 61.2% underwent restenting.
  • Restenting was associated with significantly fewer reinterventions within one year compared to angioplasty alone (HR 0.13; P = 0.003).
  • No other clinical or operative factors predicted reintervention at 12 months in univariable analysis.

Conclusions:

  • Endovascular reintervention for MAISR demonstrates high technical success and low perioperative morbidity.
  • Patients treated with restenting reported fewer symptoms of chronic mesenteric ischemia post-intervention.
  • Restenting is superior to angioplasty alone in reducing the need for reintervention within the first year for MAISR.